James Andrew Huntington

Hamilton Pharmaceuticals, Inc. develops and supplies pharmaceuticals. It also develops and commercializes novel medical treatments for central nervous system disease. The company was founded in April 2004 and is headquartered in Washington, DC.

Cellzome Ltd. engages in the research, development, and manufacture of pharmaceutical products. It provides kinase-targeted drugs to treat inflammatory diseases. The company was founded by Gitte Neubauer on December 22, 2003 and is headquartered in Middlesex, the United Kingdom.

Part of Helixmith Co., Ltd., Genebiotech Co., Ltd. is a South Korean company that develops gene and cell-based machines. The company is based in Seoul, South Korea. Genebiotech Co. was acquired by Helixmith Co., Ltd. on May 30, 2006.

Index Ventures SA (Index Ventures) is a venture capital firm founded in 1996 by Neil Alexander Rimer, Gluseppe Zocco and Gerald Rimer. The firm is headquartered in Geneva, Switzerland.

Cambridge Enterprise Ltd.(CEL) is a Venture Capital firm, a subsidiary of University of Cambridge founded in 1972. Headquartered in Cambridge.

Stealthyx Therapeutics Ltd. operates drug delivery system technology. The company was founded by Yuti Chernajovsky and Eileen Janis Anderson in 2002 and is headquartered in London, the United Kingdom.

Total Scientific Ltd. provides biomarker related research and development services. It provides services to the pharmaceutical, diagnostic, and academic communities. The firm operates as a contract research organization. Its services include biomarker discovery and clinical studies, bio analysis, data management and biostatistics, and in vivo pre-clinical services. The company was founded by David J. Grainger and David E. Mosedale in 2006 and is headquartered in Cambridge, the United Kingdom.

Epsilon-3 Bio Ltd. develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. The company was founded by Martin W. Edwards, Konstantinos Efthymiopoulos, David J. Grainger and Christian De La Tour on June 18, 2010 and is headquartered in Cambridge, the United Kingdom.

XO1 Ltd. develops a novel anticoagulant drug. The firm operates as a biopharmaceutical company. The company was founded by David J. Grainger on February 28, 2013 and is headquartered in High Wycombe, the United Kingdom.

Xenikos BV focuses on the development of immunotherapies for the treatment of patients suffering from immune diseases. It is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard, as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. The company was founded by Ypek van Oosterhout in September 2009 and is headquartered in Nijmegen, the Netherlands.

RxCelerate Ltd. provides drug development solutions. It is an out-sourced drug development company, delivering preclinical drug development programmes and project management for virtual and semi-virtual companies. The firm services include routine animal models of human diseases, toxicology and ADME studies. The company was founded by David John Grainger in April 2012 and is headquartered in Cambridge, the United Kingdom.

Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA.

Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom.

Methuselah Health UK Ltd. develops platforms for the detection of major diseases for middle and old age people. The company was founded by David John Grainger in 2015 and is headquartered in Babraham, the United Kingdom.

Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom.

Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.

Inhibitaxin Ltd. engages in research and development on biotechnology. The company was founded by Simon Lempriere Westbrook and Kevin S. Johnson in 2013 and is headquartered in Kent, the United Kingodm.

Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom.

Palladio Biosciences, Inc. develops transformative medicines for orphan diseases. Its pipeline includes Lixivaptan, a selective vasopressin V2 receptor antagonist for the treatment of polycystic kidney disease, a life-threatening genetic disease. The company was founded by Lorenzo Pellegrini in 2015 and is headquartered in Newtown, PA.

Impact Biomedicines, Inc. engages in the development of cancer treatments. It engages in the development of fedratinib, a potent and selective oral molecule JAK2 kinase inhibitor for the treatment of myelofibrosis and polycythemia vera. The company was founded by John Hood, Catriona Jamieson and Raghu Saripalli in 2016 and is headquartered in San Diego, CA.

UltraHuman Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Sandwich, the United Kingdom.

Sydnexis, Inc. engages in the production of ophthalmic pharmaceutical products. The company was founded by Gregory Isaac Ostrow in 2014 and is headquartered in San Diego, CA.

Critical Pressure Ltd. engages in research and experimental development on biotechnology. The firm develops products to treat vascular dysfunction and shock. The company is headquartered in Babraham, the United Kingdom.

Rebalance (Cambridge) Ltd. provides research and experimental development on biotechnology. The company was founded on December 6, 2016 and is headquartered in Hatfield, the United Kingdom.

Qkine Ltd. provides growth factors and bioactive proteins for use in stem cell science and regenerative medicine applications. Its products include Activin A and FGF2. The firm specializes in protein purification, organoids, cytokines, and protein-engineering. The company was founded by Marko Hyvonen and Catherine Elton in 2016 and is headquartered in Cambridge, the United Kingdom.

Human Antibody Factory Ltd. provides research and experimental development on biotechnology. The company was founded by David John Grainger and is headquartered in Hatfield, the United Kingdom.

Polyprox Therapeutics Ltd. operates as biotechnology company which engages in research and development of drugs to treat cancer and neurodegenerative diseases. The company was founded by Laura S. Itzhaki in 2018 and is headquartered in Cambridge, the United Kingdom.

Breakpoint Therapeutics GmbH engages in the discovery and development of anti-cancer drugs. It aims to advance to clinical development first-in-class oncology drugs that interfere with DNA repair and replication stress tolerance pathways. The company is headquartered in Hamburg, Germany.

Divide & Conquer Ltd. engages in processing of films. The company was founded by David John Grainger, Frank Winkler and Miroslav Radman on July 7, 2016 and is headquartered in St. Albans, the United Kingdom.

Pharmenable Ltd. operates as a drug discovery company. It designs the next generation of small molecule drugs. The company was founded by Hannah Fiona Sore, Natalia Mateu, Jelena Aleksic, David Spring, and Andreas Bender in June 2016 and is headquartered in Histon, the United Kingdom.

Spirea Ltd. operates as a healthcare technology company. It develops smart polymer platform for the controlled delivery of drug combinations to maximise the clinical impact of medicines. The company was founded by Myriam Ouberai and is headquartered in arrogate, the United Kingdom.